Trial Profile

Phase IIb trial of emapticap pegol (NOX-E36) in patients with diabetes mellitus and albuminuria

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emapticap pegol (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors TME Pharma

Most Recent Events

16 Sep 2014 New trial record
31 Jul 2014 This phase IIb study is being planned, following the completion of a phase IIa proof-of-concept study, according to a NOXXON Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com